Digilab Inc. Reaches Milestone In Biomarker Study In Lung Cancer For Abbott

Main Category: Lung Cancer
Also Included In: Cancer / Oncology
Article Date: 23 Dec 2006 - 0:00 PDT

email to a friend   printer friendly   opinions  

Digilab, Inc. today announced it has reached an important milestone in its Peptidomics collaboration with Abbott Molecular. In the first phase of the project, Digilab has identified candidate biomarkers for lung cancer using its proprietary Peptidomics(R) Differential Peptide Display (DPD) technology platform. Abbott has exercised its right to evaluate option candidate markers for further use. Abbott has the option to acquire an exclusive royalty-bearing license from Digilab to such candidate markers.

David Giddings, President and CEO of Digilab, Inc. and Dr. Wolfram Rodatz, Managing Director Digilab BioVisioN GmbH, commented on the success: "The project with Abbott now enters a promising new phase for Digilab. Our Hannover Germany based Peptidomics-approach to biomarker discovery has once again shown that it is able to provide molecular identification of peptide candidate markers very efficiently and reliably."

About Digilab

As a global leader in molecular spectroscopy systems for almost 40 years, Digilab develops innovative and differentiated products and services for the life sciences research and in-vitro diagnostics markets. The company's pioneering work for the U.S. Government in 1969 led to the development, manufacture, sales and service of the first commercial Fourier-Transform InfraRed (FTIR) spectrometer. In the fall of 2004, Digilab sold its FTIR molecular spectroscopy assets to Varian Inc. Since then, the company has remained focused on novel and proprietary sample prep, bioinformatics, and spectroscopy detection/analysis devices which can be integrated into solutions for research and diagnostics applications.

In February 2006 Digilab acquired BioVisioN, AG in Hannover, Germany. Digilab is globally commercializing Digilab BioVisioN GmbH's patented Peptidomics(R) products and services and generating IP in this space. Digilab works with companies from the pharmaceutical and diagnostics sectors; analytical instrumentation hardware, software, and consumables suppliers; and academic institutions and government agencies. Digilab has had engagements to discover new biomarkers or drug targets with such companies as Astra Zeneca, Boehringer Ingelheim, Merck & Co, Novartis, Novo Nordisk, Roche Diagnostics, Abbott, Johnson and Johnson, and Solvay Pharmaceuticals.

Digilab, Inc.
http://www.digilabglobal.com

• Additional
• References
• Citations